Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Regime abbreviato per la tubercolosi farmacosensibile nei bambini (SMILE-TB)

6 novembre 2026 aggiornato da: Johns Hopkins University

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

Panoramica dello studio

Descrizione dettagliata

In previously untreated individuals with presumed drug-susceptible pulmonary and or peripheral lymph node TB treated with eight weeks of rifapentine, isoniazid, pyrazinamide and moxifloxacin (2HPZM), all given daily throughout, the proportion of participants who experience absence of cure (unsuccessful outcome) will not be inferior to that observed in participants who are treated with the standard regimen (eight weeks of rifampin, isoniazid, pyrazinamide, with or without ethambutol followed by 8 to 16 weeks of rifampin plus isoniazid depending on disease severity) all given daily throughout.

Tipo di studio

Interventistico

Iscrizione (Stimato)

860

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Kisten Nolan, MPH, BSN
  • Numero di telefono: +14435403993
  • Email: knolan2@jh.edu

Luoghi di studio

      • Chennai, India
        • Reclutamento
        • Indian Council of Medical Research - National Institute for Research in Tuberculosis
        • Contatto:
        • Investigatore principale:
          • Aishwarya Venkataraman, MBBS, DCH, PgDip PID, MRCPCH
      • Pune, India
        • Reclutamento
        • Dr. D.Y. Patil Medical College, Hospital and Research Center
        • Contatto:
        • Investigatore principale:
          • Shailaja Mane, MBBS, MD, PGDAP, FRIPH
      • Bandung, Indonesia
        • Reclutamento
        • Faculty of Medicine, Universitas Padjadjaran
        • Contatto:
        • Investigatore principale:
          • Rovina Ruslami, MD, PhD
      • Maputo, Mozambico
        • Reclutamento
        • Instituto Nacional de Saúde (INS)
        • Contatto:
        • Investigatore principale:
          • Celso Khosa, MD, PhD
      • Durban, Sud Africa
        • Reclutamento
        • Africa Health Research Institute (AHRI)
        • Investigatore principale:
          • Moherndran Archary, MBChB, PhD
        • Contatto:
      • Kampala, Uganda
        • Reclutamento
        • MU-JHU Care Ltd
        • Contatto:
        • Investigatore principale:
          • Eric Wobudeya, MBChB MMed MSc
      • Lusaka, Zambia
        • Reclutamento
        • University of Zambia, School of Medicine
        • Contatto:
          • Chishala Chabala, MBChB MMed MSc
          • Numero di telefono: +260977849537
          • Email: cchabala@gmail.com
        • Investigatore principale:
          • Chishala Chabala, MBChB MMed MSc
      • Ndola, Zambia
        • Reclutamento
        • Arthur Davison Children's Hospital
        • Contatto:
      • Harare, Zimbabwe
        • Reclutamento
        • Harare Health and Research Consortium (HHRC)
        • Contatto:
        • Investigatore principale:
          • Mutsa Bwakura-Dangarembizi, MBChB, MMed (Paeds)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 secondo a 9 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Parent or guardian is willing and able to provide written informed consent for potential participant's study participation; in addition, when applicable per Ethics Committee/Institutional Review Board (EC/IRB) policies and procedures, potential participant is willing and able to provide assent for study participation.

  • At Entry, age of less than 10 years.

  • At Entry, weight 3 kilograms (kg) or greater.

  • At Entry, diagnosed with TB disease, defined as:

    • Pulmonary (including pleural effusion) and/or lymph node (extra-thoracic and/or intra-thoracic) TB with or without bacteriologic confirmation;
    • Clinician has decided to treat with standard first-line drug-susceptible TB regimen.
  • Known HIV status or HIV testing in progress based on meeting testing requirements.

  • Has normal, Grade 1 or 2 test results for all of the following done at or within 14 days of Entry (including the most recent):

    • Alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal;
    • Total bilirubin less than or equal to 2.5 times the upper limit of normal;
    • Potassium level of 3.0 milliequivalent/L or greater;
    • Hemoglobin level of 7.0 g/dL or greater;
    • Platelet count of 100,000/mm3 or greater;
    • Estimated glomerular filtration rate (eGFR; bedside Schwartz formula) 60 mL/min/1.73m2 or higher.
  • For children living with HIV:

    • On antiretroviral therapy (ART) at Entry: Must be on, or able to be switched to a dolutegravir-based regimen at or prior to Entry;
    • Not on ART at Entry: Planned initiation of dolutegravir before or at study Week 4.
  • For participants who have reached menarche or who are engaging in sexual activity (self-reported): negative serum or urine pregnancy test within 7 days of Entry.

  • For participants who are engaging in sexual activity that could lead to pregnancy (self-reported): agrees to practice at least one non-hormonal method of contraception or abstain from heterosexual intercourse during study drug treatment and for 30 days after stopping study medications. Non-hormonal methods include:

    • Male or female condoms
    • Diaphragm or cervical cap (with spermicide, if available)
    • Non-hormonal intrauterine device (IUD) or intrauterine system (IUS)
  • At Entry, intends to remain in the catchment area of the study site for the duration of study follow-up or willingness to be followed up beyond the catchment area if/when applicable, as determined by the site investigator based on participant/parent/guardian report.

Exclusion Criteria:

  • Presumed or documented extra-pulmonary TB involving the central nervous system and/or bones and/or joints, and/or miliary TB, and/or pericardial TB and/or TB of the gastrointestinal (GI) tract and/or renal TB.

  • Premature infant (born less than 37-weeks gestation) who is less than 3 months of age at Entry.

  • Any known contraindication to taking any study drug:

    • Known allergy or intolerance to any of the study drugs or drugs in the same class as the study drugs;
    • Any prohibited medications within three days prior to Entry or planned use within the following 6 months;
    • Unable to take oral medications;
    • Known history of prolonged QT syndrome not caused by electrolyte derangements.
  • Received more than 10 days of treatment directed against TB disease within 6 months preceding initiation of study drugs.

  • M. tuberculosis isolate known or suspected to be resistant to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Known exposure to an infectious adult with drug-resistant TB, including resistance to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Has any other documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

  • Previously enrolled in this study.

Late Exclusions:

  • M. tuberculosis cultured or detected through World Health Organization (WHO) approved molecular assays (e.g., Cepheid Xpert MTB/RIF, Xpert XDR, sequencing or Hain MTB-DR plus assays) from sputum, swallowed sputum, nasopharyngeal aspirates, stool, or lymph node aspirate obtained around the time of study entry is determined to be resistant to isoniazid and/or rifampin and/or pyrazinamide and/or ethambutol and/or fluoroquinolones.
  • Any child with a clinical TB diagnosis who is found to have a definitive alternative diagnosis for their presenting signs and symptoms whose TB treatment is discontinued prior to completion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Regimen 1: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E)

8 weeks of daily HRZ(E) followed by either 16 or 24 weeks of daily HR, per local standard of care

Once daily weight-based dose

Altri nomi:
  • H

Once daily weight-based dose

Altri nomi:
  • R

Once daily weight-based dose

Altri nomi:
  • Z

Once daily weight-based dose

Altri nomi:
  • E
Sperimentale: Regimen 2: Isoniazid (H), Rifapentine (P), Pyrazinamide (Z), Moxifloxacin (M)

8 weeks of daily HPZM

Once daily weight-based dose

Altri nomi:
  • H

Once daily weight-based dose

Altri nomi:
  • Z

Once daily weight-based dose

Altri nomi:
  • Priftin
  • P

Once daily weight-based dose

Altri nomi:
  • Avelox
  • M

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
TB disease-free survival at 48-weeks
Lasso di tempo: Measured from study entry through week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through week 48
Proportion of participants with grade 3 or higher adverse events over 28 weeks
Lasso di tempo: Measured from study entry through Week 28

The proportion of participants with a Grade 3 or higher adverse event and the corresponding 95% confidence intervals will be generated. An exact test for equality of proportions will be used to compare safety outcomes between the arms.

Measured from study entry through Week 28

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
TB disease-free survival at 48-weeks
Lasso di tempo: Measured from study entry through Week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through Week 48
TB disease-free survival at 72-weeks
Lasso di tempo: Measured from study entry through Week 72

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 72 weeks.

Measured from study entry through Week 72
Adherence to treatment regimens
Lasso di tempo: Measured from study entry through Week 48

The per-protocol analysis will account for variations in adherence to the treatment regimens. Inverse probability of treatment weighting (IPTW) using propensity scores will be applied and the net difference in treatment failure rates between the two treatment regimens and the 95% confidence interval around this will be calculated to determine non-inferiority.

Measured from study entry through Week 48
Tolerability as assessed by proportion of participants who discontinue treatment
Lasso di tempo: Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))

Tolerability will be assessed as discontinuation of the assigned treatment for a reason other than microbiological ineligibility (AEs assessed as related to the study regimen that led to permanent discontinuation of the regimen, participant refusal, parent/guardian prematurely discontinues, etc.) among the modified intention-to-treat population. Proportion of participants who discontinue the assigned study regimen and the corresponding 95% confidence intervals will be generated. The control regimen (HRZ(E)) will be compared against the intervention regimen (HPZM) using an exact test for equality of proportions.

Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))
Rifapentine Area under the curve (AUC0-24)
Lasso di tempo: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine minimal concentration (Cmin)
Lasso di tempo: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine peak concentration (Cmax)
Lasso di tempo: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin AUC0-24
Lasso di tempo: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmin
Lasso di tempo: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmax
Lasso di tempo: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Parent/guardian and/or participant reported palatability and acceptability of study regimen
Lasso di tempo: Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)

Based on questionnaire developed by study team, data will be aggregated to measure acceptability at Entry, Week 4, and Week 8 (all participants), and Weeks 16 and 24 (for those who continue on HRZ(E) only). Scoring based on a likert or likert-like scale for each question. Each question is scored 1 to 5 with higher scores reflecting increased acceptability.

Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)
Adherence as assessed by proportion of participants who have taken at least 90% of their doses
Lasso di tempo: Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease

Adherence measures will be documented by a treatment supporter on a TB treatment card (as per local practice), by pill count and by an adherence questionnaire and descriptively summarized for all participants. Participants are considered adherent who have taken at least 90% of their doses within the 8 week, 16 week or 24-week time frame of their regimen.

Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease
Risk Stratification Algorithm
Lasso di tempo: Measured from study entry through Week 48

If the study outcome is not non-inferior, pragmatic, programmatically available data will be considered for inclusion in a risk stratification algorithm that would aim to identify children at high risk of unsuccessful TB treatment outcome who may benefit from a longer duration of therapy. The efficacy endpoint will be analyzed using mixed-effects logistic regression models to identify predictors. The models will be adjusted for World Bank country income categories and by site using random intercepts. Univariable and multivariable analysis will be performed. The association between baseline clinical predictors and unsuccessful treatment outcomes will be analyzed, Treatment characteristics will then be added to the models to determine if treatment helped in the description of the primary efficacy endpoint.

Measured from study entry through Week 48
Cost effectiveness as assessed by the incremental cost-effective ratio (ICER)
Lasso di tempo: Measured from study entry through Week 24

ICER: Total costs of HPZM minus the total costs 16 or 24 week HRZE, divided by the total number of disability-adjusted life-year (DALY) averted for HPZM minus the total DALYs averted for 16- or 24-week HRZE.

Measured from study entry through Week 24

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Dolutegravir AUC0-24
Lasso di tempo: Measured from study entry through Week 28

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmin
Lasso di tempo: Measured from study entry through Week 28

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmax
Lasso di tempo: Measured from study entry through Week 28

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Proportion of children living with HIV
Lasso di tempo: Week 24 and Week 48

Among participants living with HIV, the proportions of participants in each study arm who achieve or maintain virologic control (< 200 copies/mL) at Weeks 24 and 48 will be presented in aggregate, as well as broken down by weight bands (if the sample sizes are sufficient) bounded by 95% confidence intervals.

Week 24 and Week 48

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Nicole Salazar-Austin, MD, ScM, Johns Hopkins University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 gennaio 2025

Completamento primario (Stimato)

30 settembre 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

26 gennaio 2024

Primo inviato che soddisfa i criteri di controllo qualità

2 febbraio 2024

Primo Inserito (Effettivo)

12 febbraio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Make individual participant data, after de-identification, publicly available in accordance with USAID's policy on data sharing.

Periodo di condivisione IPD

After study completion, de-identified data that can be legally released to the public may be released.

Criteri di accesso alla condivisione IPD

With whom: Researchers who provide a methodologically sound proposal for the use of the data per USAID's policy on data sharing and in accordance with in-country data sharing agreements.

For what types of analysis: To achieve aims specified in the researcher's approved proposal.

By what mechanisms will data be available: To be determined.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi